Patents by Inventor Elaine Lynette Wilson

Elaine Lynette Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160222461
    Abstract: The prognosis of a cancer patient can be determined by analyzing the modulation of expression of specified genes in the tumor tissue. Genes uniquely up-regulated in adult stem cells that can reconstitute the tissue of the tumor are analyzed for up-regulation in the patient's tumor. Up-regulation of a plurality of such genes in the tumor is an indication of good prognosis. Genes uniquely up-regulated in fetal stem cells are analyzed for up-regulation in the patient's tumor. Up-regulation of a plurality of such genes in the tumor are an indication of a poor prognosis. Specific genes are disclosed, the modulation of which, in a patient's prostate cancer tumor, will serve as an indication of prognosis. Patients with a good prognosis are subjected to watchful waiting. Patients with a poor prognosis are aggressively treated. Kits are provided containing a set of affinity reagents that specifically detect expression of the various genes.
    Type: Application
    Filed: November 30, 2015
    Publication date: August 4, 2016
    Inventors: Elaine Lynette Wilson, Liliana Ossowski, Phillip Ross Smith
  • Patent number: 9200328
    Abstract: The prognosis of a cancer patient can be determined by analyzing the modulation of expression of specified genes in the tumor tissue. Genes uniquely up-regulated in adult stem cells that can reconstitute the tissue of the tumor are analyzed for up-regulation in the patient's tumor. Up-regulation of a plurality of such genes in the tumor is an indication of good prognosis. Genes uniquely up-regulated in fetal stem cells are analyzed for up-regulation in the patient's tumor. Up-regulation of a plurality of such genes in the tumor are an indication of a poor prognosis. Specific genes are disclosed, the modulation of which, in a patient's prostate cancer tumor, will serve as an indication of prognosis. Patients with a good prognosis are subjected to watchful waiting. Patients with a poor prognosis are aggressively treated. Kits are provided containing a set of affinity reagents that specifically detect expression of the various genes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 1, 2015
    Assignee: NEW YORK UNIVERSITY
    Inventors: Elaine Lynette Wilson, Liliana Ossowski, Phillip Ross Smith
  • Patent number: 8067230
    Abstract: Prostatic stem cells have been isolated. Benign prostatic hyperplasia and other proliferative diseases of the prostate may arise in prostatic stem cells. The prostatic stem cells are used as a research tool for studying cancer and other proliferative diseases of the prostate, and for developing diagnostics and therapeutics for proliferative diseases of the prostate. Antibodies to the antigens expressed by prostatic stem cells can be used as therapeutics or diagnostics or can be used to deliver therapeutic or diagnostic agents directly to the prostatic stem cells.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: November 29, 2011
    Assignee: New York University
    Inventors: Elaine Lynette Wilson, Patricia Burger
  • Publication number: 20080194710
    Abstract: Prostatic stem cells have been isolated. Benign prostatic hyperplasia and other proliferative diseases of the prostate may arise in prostatic stem cells. The prostatic stem cells are used as a research tool for studying cancer and other proliferative diseases of the prostate, and for developing diagnostics and therapeutics for proliferative diseases of the prostate. Antibodies to the antigens expressed by prostatic stem cells can be used as therapeutics or diagnostics or can be used to deliver therapeutic or diagnostic agents directly to the prostatic stem cells.
    Type: Application
    Filed: May 10, 2005
    Publication date: August 14, 2008
    Applicant: NEW YORK UNIVERSITY
    Inventors: Elaine Lynette Wilson, Patricia Burger
  • Patent number: 5817773
    Abstract: Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: October 6, 1998
    Assignees: New York University, Sloan-Kettering Institute for Cancer Research
    Inventors: Elaine Lynette Wilson, Janice Gabrilove